Abstract
P21+/MCM2− cell content improves risk stratification in intermediate-risk ccRCC. Kaplan–Meier survival analysis in the SORCE training cohort (n = 63) shows that patients with ≤2% P21+/MCM2− cells experienced significantly higher relapse rates than those with >2% (P < 0.001) within 142 months. In contrast, stratification by the raw LS (LS 3–5) demonstrated a trend that was not statistically significant (P = 0.21). Box-and-whisker plots reveal overlapping distributions of P21+/MCM2− cell percentages across LS subgroups. In the Korean validation cohort (n = 71), the same 2% threshold also significantly stratified outcomes (P = 0.005) within 195 months.